UofT Talks

A randomized clinical trial of repeated doses of psilocybin for the treatment of obsessive–compulsive disorder 🍥"Administration of up to eight doses of psilocybin in a clinical research setting appears to be safe and potentially effective for patients with OCD. Larger trials are needed to further support efficacy and refine treatment protocols." journals.sagepub.com/doi/10.…

Researchers have been exploring whether psilocybin, the psychoactive compound in some mushrooms can help people with severe, treatment-resistant depression. In one small clinical study, participants who hadn’t responded to standard therapies were given two supervised doses. The outcomes were notable. Many reported meaningful relief from depressive symptoms that lasted for several weeks after treatment. What stood out even more to scientists were the observable changes in the brain. Brain imaging revealed shifts in activity and connectivity within just a day. Areas associated with fear and stress, such as the amygdala, became less active, while communication between different brain networks appeared more coordinated and stable. Participants often described the experience in everyday terms, like a mental “reset” or “reboot.” Some felt as though rigid, negative thought patterns had been loosened or temporarily disrupted. Researchers believe this may reflect what’s happening neurologically. During the psychedelic state, typical brain networks become less fixed and more flexible. As the effects wear off, these networks reorganize, which may help people move beyond entrenched patterns linked to depression. However, there are important limitations. The study involved only around 20 participants and did not include a placebo comparison, so the findings are still preliminary. The treatment was also conducted in a controlled clinical environment with professional psychological support. Even so, the results add to a growing line of research suggesting psychedelics could represent a different approach to mental health treatment—one that works not by dampening symptoms, but by helping the brain reconfigure itself.